Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

ProMIS Neurosciences Inc. - news published 198 - readings 1.897

BACK

ProMIS Neurosciences Inc.

FY 2024

March 31, 2025 ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, M ...

31.03.2025

ProMIS Neurosciences Inc.

Supplemental Prospectus (Form 424B5)

Table of Contents PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To prospectus supplement dated January 5, 2024 To Prospectus dated September 29, 2023) Registration No. 333-274658 PROMIS NEUROSCIENCES INC. Up to $10,354,794 Common Shares This prospectus supplement amends and supplements the information in the prospectus, dated September 29, 2023, filed with the Se ...

31.03.2025

ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights (Form 8-K)

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts - March 31, 2025 ...

31.03.2025

ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

31.03.2025

ProMIS Neurosciences Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

Management's Discussion and Analysis of Financial Condition and Results of Operations All references in this management's discussion and analysis of financial condition and results of operations, or MD&A, to the "Company", "ProMIS", "we", "us", or "our" refer to ProMIS Neurosciences Inc., unless otherwise indicated or the c ...

31.03.2025

ProMIS Neurosciences Inc.

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

March 24, 2025 ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference Multiple datasets support continued development of ProMIS' antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative ...

24.03.2025

ProMIS Neurosciences Inc.

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

March 13, 2025 ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting CAMBRIDGE, Massachusetts , March 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody the ...

13.03.2025

ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

March 11, 2025 ProMIS Neurosciences to Participate in the 37th Annual Roth Conference CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's ...

11.03.2025

ProMIS Neurosciences Inc.

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

February 25, 2025 ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer's Disease Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026 CAMBRIDGE, Massachusetts, Fe ...

25.02.2025

ProMIS Neurosciences Inc.

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease (Form 8-K)

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer's Disease Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026 CAMBRIDGE, Massachusetts - February 25, 2025 - ...

25.02.2025

ProMIS Neurosciences Inc.

Management Change/Compensation (Form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 14, 2025, ProMIS Neurosciences Inc. (the "Company") separated with Gavin T. Malenfant as Chief Operating Officer of the Company, effective as of February 14, 2025 (the "Separation"). In con ...

19.02.2025

ProMIS Neurosciences Inc.

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

12.02.2025

ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

January 29, 2025 ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases ...

29.01.2025

ProMIS Neurosciences Inc.

Corporate Overview

Targeting the underlying cause of neurodegenerative diseases NASDAQ: PMN Legal Disclaimers This slide deck may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore ...

27.01.2025

ProMIS Neurosciences Inc.

Regulation FD Presentation (Form 8-K)

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer ProMIS Neurosciences Inc. published this content on January 27, 2025 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 27, 2025 at 12:32:26.790 .

27.01.2025

ProMIS Neurosciences Inc. - news published 198 - readings 1.897

ProMIS Neurosciences Inc.

FY 2024

ProMIS Neurosciences Inc.

Supplemental Prospectus (Form 424B5)

ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights (Form 8-K)

ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

ProMIS Neurosciences Inc.

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

ProMIS Neurosciences Inc.

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

ProMIS Neurosciences Inc.

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

ProMIS Neurosciences Inc.

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease (Form 8-K)

ProMIS Neurosciences Inc.

Management Change/Compensation (Form 8-K)

ProMIS Neurosciences Inc.

Statement of Changes in Beneficial Ownership (Form 4)

ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

ProMIS Neurosciences Inc.

Corporate Overview

ProMIS Neurosciences Inc.

Regulation FD Presentation (Form 8-K)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member